Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Simple item page
dc.contributor.authorJara, Alejandro
dc.contributor.authorUndurraga, Eduardo A.
dc.contributor.authorGonzalez, Cecilia
dc.contributor.authorParedes, Fabio
dc.contributor.authorFontecilla, Tomas
dc.contributor.authorJara, Gonzalo
dc.contributor.authorPizarro, Alejandra
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorLeo, Katherine
dc.contributor.authorLeon, Francisco
dc.contributor.authorSans, Carlos
dc.contributor.authorLeighton, Paulina
dc.contributor.authorSuarez, Pamela
dc.contributor.authorGarcia Escorza, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2024-01-10T12:37:04Z
dc.date.available2024-01-10T12:37:04Z
dc.date.issued2021
dc.description.abstractInactivated SARS-CoV-2 Vaccine in Chile In a national prospective cohort study involving 10.2 million participants in Chile, the effectiveness of an inactivated SARS-CoV-2 vaccine, which had been developed in China and administered in two doses 28 days apart, was estimated. Effectiveness among fully immunized persons was estimated at 65.9% for Covid-19 and at 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.
dc.description.abstractBackground Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021. Methods We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (>= 14 days after receipt of the first dose and before receipt of the second dose) and full immunization (>= 14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics. Results The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19-related death. Conclusions Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigacion y Desarrollo and others.)
dc.description.funderAgencia Nacional de Investigacion y Desarrollo (ANID) Millennium Science Initiative Program
dc.description.funderMillennium Nucleus Center for the Discovery of Structures in Complex Data (MIDAS)
dc.description.funderMillennium Initiative for Collaborative Research in Bacterial Resistance (MICROB-R)
dc.description.funderAdvanced Center for Chronic Diseases
dc.description.funderANID Fondo de Financiamiento de Centros de Investigacion en Areas Prioritarias (FONDAP)
dc.description.funderResearch Center for Integrated Disaster Risk Management ANID FONDAP
dc.fechaingreso.objetodigital2024-04-25
dc.format.extent10 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1056/NEJMoa2107715
dc.identifier.eissn1533-4406
dc.identifier.issn0028-4793
dc.identifier.pubmedidMEDLINE:34233097
dc.identifier.urihttps://doi.org/10.1056/NEJMoa2107715
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76740
dc.identifier.wosidWOS:000672656600001
dc.information.autorucFacultad de Matemáticas; Jara Vallejos, Alejandro Antonio; S/I; 127927
dc.issue.numero10
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final884
dc.pagina.inicio875
dc.publisherMASSACHUSETTS MEDICAL SOC
dc.revistaNEW ENGLAND JOURNAL OF MEDICINE
dc.rightsacceso restringido
dc.subjectCOVID-19
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
dc.typeartículo
dc.volumen385
sipa.codpersvinculados127927
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-04-25. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.pdf
Size:
3.42 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas